scholarly journals Thyroid hormone autoantibodies (THAA) in two cases of Graves' disease: Effects of antithyroid drugs, prednisolone, and subtotal thyroidectomy.

1986 ◽  
Vol 33 (6) ◽  
pp. 751-759 ◽  
Author(s):  
SHIGENORI NAKAMURA ◽  
SHIGEKI SAKATA ◽  
HIROTO SHIMA ◽  
TAKASHI KOMAKI ◽  
NORIKO KOJIMA ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Subtotal Thyroidectomy ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Thyroid Hormone Autoantibodies

A Study on Thyroid Hormone Autoantibodies in Patients with Hashimoto's Disease and Graves' Disease

1983 ◽  
Vol 59 (10) ◽  
pp. 1597-1607 ◽  
Author(s):  
Shigenori NAKAMURA ◽  
Masanori MURAYAMA ◽  
Noriko KOJIMA ◽  
Keita KAMIKUBO ◽  
Shigeki SAKATA ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Graves Disease ◽  
Hashimoto’S Disease ◽  
Thyroid Hormone Autoantibodies ◽  
Hashimoto's Disease

scholarly journals Thyroid Hormone Autoantibodies in Patients with Untreated Graves' Disease: with Special Reference to Age.

1993 ◽  
Vol 40 (3) ◽  
pp. 337-342 ◽  
Author(s):  
SHIGENORI NAKAMURA ◽  
JUNKO HATTORI ◽  
TORU OGAWA ◽  
SHIGEKI SAKATA
Keyword(s):  
Thyroid Hormone ◽  
Special Reference ◽  
Graves Disease ◽  
Thyroid Hormone Autoantibodies

Thyroid hormone autoantibodies in patients with Graves' disease: effect of anti-thyroid drug treatment

1994 ◽  
Vol 228 (2) ◽  
pp. 113-122 ◽  
Author(s):  
Toru Ogawa ◽  
Shigeki Sakata ◽  
Shigenori Nakamura ◽  
Hiroshi Takuno ◽  
Ikuo Matsui ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Drug Treatment ◽  
Graves Disease ◽  
Thyroid Hormone Autoantibodies ◽  
Disease Effect

Lower Incidence of Postpartum Thyrotoxicosis in Women With Graves Disease Treated by Radioiodine Therapy Than by Subtotal Thyroidectomy or With Antithyroid Drugs

2014 ◽  
Vol 39 (4) ◽  
pp. 326-329 ◽  
Author(s):  
Ai Yoshihara ◽  
Jaeduk Yoshimura Noh ◽  
Natsuko Watanabe ◽  
Kenji Iwaku ◽  
Sakiko Kobayashi ◽  
...  
Keyword(s):  
Lower Incidence ◽  
Radioiodine Therapy ◽  
Subtotal Thyroidectomy ◽  
Antithyroid Drugs ◽  
Graves Disease

scholarly journals Two Cases of Graves' Disease with Anti-thyroid Hormone Autoantibodies

1989 ◽  
Vol 65 (11) ◽  
pp. 1219-1225
Author(s):  
Kotaro NAGAI ◽  
Hiroyuki MAEKAWA ◽  
Masaaki KAMETANI ◽  
Naoki TOKIMITSU ◽  
Takashi KOMAKI ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Graves Disease ◽  
Thyroid Hormone Autoantibodies

scholarly journals HIPERTIROIDISMEE GRAVES DISEASE:CASE REPORT

2020 ◽  
Vol 6 (1) ◽  
pp. 30-35
Author(s):  
Putri Rahayu Srikandi
Keyword(s):  
Case Report ◽  
Thyroid Hormone ◽  
Thyroid Gland ◽  
Physical Examination ◽  
Clinical Condition ◽  
Laboratory Tests ◽  
Clinical Manifestations ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Thyroid Hormone Levels

AbstractAbstrak:Hipertiroid adalah kondisi klinis yang disebabkan peningkatan sintesis dan sekresi hormone oleh kelenjar tiroid, sedangkan tirotoksikosis mengacu pada manifestasi klinis.  Penyakit graves merupakan penyebab hipertiroid yang paling sering ditemukan sekitar 60-80% dari semua kasus tirotoksikosis di seluruh dunia. Pada laporan kasus ini akan dibahas pasien Ny. NMS berusia 56 tahun datang dengan keluhan dada berdebar-debar yang dirasakan sejak 3 minggu yang lalu dan pada pemeriksaan fisik didapatkan adanya pembesaran kelenjar tiroid dan indeks Wayne pada kasus ini didapatkan  21. Pada pemeriksaan laboratorium didapatkan kadar Tyroid Stimulating Hormone (TSH) 0,005 uIU/ml, , dan free Tiroksin (fT4) 7,77mg/dl. Penatalaksanaan pada kasus ini yaitu pasien diberikan tyrozol  3x10 mg sehari dan propanolol 3x10mg. Kata kunci: graves, hipertiroidism, tirotoksikosis AbstractHipertiroidisme is a clinical condition caused by increased synthesis and secretion of hormones by the thyroid gland. Thyrotoxicosis is defined as clinical manifestations related to increased thyroid hormone levels. Graves' disease (GD) persists as the most frequently encountered etiology of hipertiroidisme causing approximately 60-80% of all cases of thyrotoxicosis worldwide. In this case report we will discuss woman patient Mrs.NMS aged 56 years with complaints of palpitations felt since three weeks ago and physical examination found enlargement of the thyroid gland and Wayne index in this case obtained 21. In laboratory tests found levels of TSH 0.005 uIU/ml and T4 7.77 mg/dl. Principle in the treatment of hipertiroidisme is suppressing the production of thyroid hormone by using antithyroid drugs. Management in this case that the patient is given 3x10 mg Thyrozol and propranolol 3x10 mg. Keywords: graves, hipertiroidisme, thyrotoxicosis

High iodine (substrate) turnover Graves' disease: the intriguing ‘rapid responder’ variant of thyrotoxicosis

2008 ◽  
Vol 45 (6) ◽  
pp. 612-615 ◽  
Author(s):  
Rinkoo Dalan ◽  
Melvin Khee-Shing Leow ◽  
David Chee-Eng Ng
Keyword(s):  
Thyroid Hormone ◽  
Low Dose ◽  
Clinical Course ◽  
Pharmacological Intervention ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
High Turnover ◽  
High Iodine ◽  
Expert Clinician ◽  
Hormone Responses

Factors determining the responsiveness to antithyroid drugs (ATDs) in Graves' disease are not fully known. Notwithstanding the typical pattern and tempo of thyroid hormone responses to thionamides, the existence of an unusual subset of Graves' disease with extraordinarily rapid thyroid hormone responses to ATDs will prove challenging even to the expert clinician. Termed ‘rapid responder Graves' disease’ or ‘high turnover Graves' disease’, the serum thyroxine (FT4) and triiodothyronine (FT3) of patients with this variant of thyrotoxicosis can decline precipitously during the initiation of ATDs and yet escalate acutely upon discontinuation of pharmacological intervention. We describe a case that presented with low serum FT4 and FT3 in association with suppressed serum thyrotropin (TSH) concentrations soon after starting carbimazole even at a low dose. The erratic clinical course comprising largely of serum FT4 nadirs and peaks is elaborated to facilitate appreciation of the difficulty in the stabilization of the thyroid with ATDs. The possible pathogenetic mechanisms for the chaotic fluctuations in thyroid hormones to minor changes in thionamide dose adjustments are discussed as well.

Triiodothyronine autoantibodies in Graves' disease: Their changes after antithyroid therapy and relationship with the thyroglobulin antibodies

1990 ◽  
Vol 122 (1) ◽  
pp. 22-28 ◽  
Author(s):  
Pei-Wen Wang ◽  
Miau-Ju Huang ◽  
Rue-Tsuan Liu ◽  
Chung Dar Chen
Keyword(s):  
Thyroid Hormone ◽  
Antigenic Site ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Thyroglobulin Antibodies ◽  
Control Subjects ◽  
Antithyroid Therapy ◽  
Positive Antibody ◽  
Antithyroid Treatment

Abstract. Sera of 63 patients with Graves' disease, and 49 control subjects were assayed for T3 autoantibodies by a sensitive radioimmunoassay after being stripped of the endogenous thyroid hormone. T3 autoantibodies were demonstrated in 27% of patients with Graves' disease. After antithyroid treatment, T3 autoantibodies in 75% of the patients with positive antibody before therapy changed to negative titre during a follow-up period of 1 to 12 months. Also, a significant decrease of T3 autoantibodies was observed at 1 month after therapy in all patients who received antithyroid treatment. A further study of T3 autoantibodies and anti-thyroglobulin antibodies showed that the latter were demonstrated in 100% of patients with positive T3 autoantibodies and that T3 autoantibodies existed in about one third of patients with positive anti-thyroglobulin antibodies. The results suggested that T3 autoantibodies could be a subpopulation of the heterogenous anti-thyroglobulin antibodies. Although the fall of T3 autoantibodies in some patients was correlated to that of anti-thyroglobulin antibodies, the overall correlation between T3 autoantibodies and anti-thyroglobulin antibodies was poor. In conclusion: 1. T3 autoantibodies may be suppressed by antithyroid drugs. 2. Being a subpopulation of anti-thyroglobulin antibodies, T3 autoantibodies may be caused by an antigenic site within the big thyroglobulin molecule, whereas their titre was not correlated with that of the overall heterogenous anti-thyroglobulin antibodies.

scholarly journals Value of total thyroidectomy for Graves' disease in eliminating the risk of recurrence and malignancy: retrospective database analysis of 574 Saudi Arabian patients in 10 years with 2 years follow up

2016 ◽  
Vol 2 (1) ◽  
pp. 6 ◽  
Author(s):  
Bader Hamza Shirah ◽  
Hamza Assad Shirah
Keyword(s):  
Total Thyroidectomy ◽  
Saudi Arabian ◽  
Subtotal Thyroidectomy ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Database Analysis ◽  
Risk Of Recurrence ◽  
Retrospective Database Analysis ◽  
Retrospective Database

<p class="abstract"><strong>Background:</strong> Graves' disease is an autoimmune disease that affects the thyroid gland and frequently results in hyperthyroidism and an enlarged thyroid. Treatment of Graves' disease includes antithyroid drugs, radioiodine (radioactive iodine I-131), and thyroidectomy, either total, or subtotal excision. In this paper, we aim to analyse the outcome of thyroidectomy performed on patients affected by Graves' disease in Medina – Saudi Arabia, and evaluate if thyroidectomy should be considered the first treatment option for all patients with Graves' disease.</p><p class="abstract"><strong>Methods:</strong> A retrospective database analysis of the surgical treatment outcome of 574 Saudi Arabian patients who were affected with Graves' disease between January 2003 and December 2012 was done. The computerized database medical records were reviewed and analysed for preoperative, intraoperative, and postoperative factors.  </p><p class="abstract"><strong>Results:</strong> 194 (33.8%) patients were males, and 380 (66.2%) were females. The average age of patients was 44 ± 2 years. 154 (26.8%) had subtotal thyroidectomy, and 420 (73.2%) had total thyroidectomy performed. There was (0%) recurrent laryngeal nerve injury, and (0%) intraoperative complication were recorded. With a follow up time of 2 years, 7 (1.22%) patients developed recurrent disease (all in subtotal thyroidectomy group). There were no recurrences in the total thyroidectomy patients, and 11 (1.9%) patients were found in histopathology to have papillary thyroid cancer (all in total thyroidectomy group).</p><p><strong>Conclusions:</strong> We conclude that total thyroidectomy is a safe and effective treatment modality for Graves' disease that offers rapid and long-lasting results, in addition to eliminating the risk of recurrence and malignancy. It should be offered to all confirmed Graves' disease patients during counselling.</p>

Sign in / Sign up

Export Citation Format

Share Document